Viewtran Group Inc  

(Public, NASDAQ:VIEW)   Watch this stock  
Find more results for NASDAQ:COGO
-0.05 (-2.40%)
Apr 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.03 - 2.08
52 week 1.70 - 2.85
Open 2.07
Vol / Avg. 111,367.00/79,533.00
Mkt cap 59.47M
P/E 18.10
Div/yield     -
EPS 0.11
Shares 29.30M
Beta 1.78
Inst. own 8%

Key stats and ratios

Q2 (Jun '13) 2012
Net profit margin 1.34% 1.00%
Operating margin 1.65% 1.37%
EBITD margin - 2.00%
Return on average assets 2.44% 1.98%
Return on average equity 2.67% 1.59%
Employees 540 -
CDP Score - -


Room 10001, Tower C Skyworth Building High-Tech Industrial Park
+86-755-26988211 (Phone)
+86-755-26743522 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Viewtran Group Inc, formerly Cogo Group, Inc., is a provider of supply chain financial services and enterprise solutions for the technology industry in China. The Company works with manufacturers and distributors to provide working capital and extended-term financing programs. Through its finance programs, manufacturers and distributors may reduce credit exposure and shift risk off their balance sheets by selling accounts receivables to the Company; provide growth capital to resellers without increased credit risk by accessing credit lines and providing longer payment terms with vendors; outsource to the Company credit administration and receivables collection and management, and outsource to the Company import and export custom clearance, finance import tax payment and tax-refund collection services.

Officers and directors

Jeffrey Kang Chairman of the Board, Chief Executive Officer
Age: 41
Bio & Compensation  - Reuters
Yi Yuan President
Age: 47
Bio & Compensation  - Reuters
Andy Liu Chief Financial Officer, Director
Bio & Compensation  - Reuters
J. P. Gan Independent Director
Age: 40
Bio & Compensation  - Reuters
Q. Y. Ma Ph.D. Independent Director
Age: 54
Bio & Compensation  - Reuters
George Mao Independent Director
Age: 49
Bio & Compensation  - Reuters